ArticleFrontiers in bioengineering and biotechnology2019
Engineering the Yeast
Article in Frontiers in bioengineering and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 97 citations in OpenAlex.
- Metabolic engineering ofSynthetic and systems biotechnology · 2026Article
- Edible Fungi and Skin Redox Homeostasis: Bioactive Diversity, Processing, Oral Exposure, and Evidence Gaps.Antioxidants (Basel, Switzerland) · 2026Review
- Ergothioneine: Biosynthesis, Molecular Mechanisms, Physiological Function, and Role in Disease.MedComm · 2026Review
- A hybrid system enables plasmid copy number control in yeast.Nature communications · 2026Article
- A yeast-based oral vaccine platform reveals antigen-dependent protection against Eimeria tenella.Poultry science · 2026Article
- Engineering Komagataella phaffii for secreted and surface-displayed production of SARS-CoV-2 receptor-binding domain and its immunogenicity evaluation.Microbial cell factories · 2026Article
- Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae.Chembiochem : a European journal of chemical biology · 2026Review
- Enhancement of ergothioneine production in Corynebacterium glutamicum by increasing osmotic pressure.Applied microbiology and biotechnology · 2025Article
- Polyphosphate Accumulation Is Determined by Zinc and Inositol in Saccharomyces cerevisiae.Yeast (Chichester, England) · 2025Article
- CRISPR/Cas9-based iterative multi-copy integration for improved metabolite yields inSynthetic and systems biotechnology · 2025Article
- A Review of Novel Antioxidant Ergothioneine: Biosynthesis Pathways, Production, Function and Food Applications.Foods (Basel, Switzerland) · 2025Review
- Biosynthesis of ergothioneine: current state, achievements, and perspectives.Applied microbiology and biotechnology · 2025Review
- Heterologous and High Production of Ergothioneine inMetabolites · 2025Article
- Ergothioneine biosynthesis: The present state and future prospect.Synthetic and systems biotechnology · 2025Review
- The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects.International journal of molecular sciences · 2024Review
- AdvancingBioengineering (Basel, Switzerland) · 2024Review
- Engineering non-conventional yeast Rhodotorula toruloides for ergothioneine production.Biotechnology for biofuels and bioproducts · 2024Article
- Impact of cell wall polysaccharide modifications on the performance of Pichia pastoris: novel mutants with enhanced fitness and functionality for bioproduction applications.Microbial cell factories · 2024Article
- Biosynthetic ability of diverse basidiomycetous yeast strains to produce the natural antioxidant ergothioneine.AMB Express · 2024Article
- Engineering strategies for enhanced heterologous protein production by Saccharomyces cerevisiae.Microbial cell factories · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-(+)-Ergothioneine (ERG) is an unusual, naturally occurring antioxidant nutraceutical that has been shown to help reduce cellular oxidative damage. Humans do not biosynthesise ERG, but acquire it from their diet; it exploits a specific transporter (SLC22A4) for its uptake. ERG is considered to be a nutraceutical and possible vitamin that is involved in the maintenance of health, and seems to be at too low a concentration in several diseases
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.